Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imugene (IMU) raises $90 million through its placement to funds its programs through to the end of 2025
  • The placement received strong support from several specialist biotech institutional investors, who cornerstoned the capital raising
  • Under the placement, the company will issue 300 million new shares at 30 cents each
  • Additionally, the company is aiming to raise a further $5 million through a share purchase plan
  • Just as the market opens, Imugene was trading in the grey at 33 cents per share

Imugene (IMU) has raised $90 million through its placement and plans to raise a further $5 million more.

The clinical-stage immuno-oncology company will issue 300 million new shares at 30 cents each.

The placement received strong support from several specialist biotech institutional investors who cornerstoned the capital raising.

Following the placement is a share purchase plan (SPP) aiming to raise $5 million.

Under the placement and SPP, participants will receive one free option for every two shares subscribed.

Funds from the raise will be used for Imugene's range of programs through to the end of 2025. This includes trials for HER-Vaxx, PD-1-Vaxx, CHECKvacc, Vaxinia and OnCARlytics, as well as associated manufacturing, regulatory and working
capital costs.

CEO Paul Hopper said the capital raising is a "game changer" for Imugene.

"It’s a credit to the groundwork done by Leslie and the rest of the team in recent years. We’ve been able to attract some high quality, specialist shareholders in the life sciences sector, and I’d like to welcome those new shareholders as well as thanking our existing shareholders for their continued support."

Just as the market opens, Imugene was trading in the grey at 33 cents per share at 10:03 am AEST.

IMU by the numbers
More From The Market Herald
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon - The Market Herald

" ImpediMed (ASX:IPD) initiates SOZO heart failure program

ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.    
Invex Therapeutics (ASX:IXC) - Chairman, Jason Loveridge - The Market Herald

" Invex Therapeutics (ASX:IXC) pens agreement for commercialisation of Presedin

Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.
LBT Innovations (ASX:LBT) - CEO and MD, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) subsidiary appoints US distributor

LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System (CCS), has appointed Thermo Fisher Scientific as its US distributor.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett - The Market Herald

" Paradigm Biopharma (ASX:PAR) receives FDA feedback for knee osteoarthritis drug

Paradigm Biopharmaceuticals (PAR) has received feedback from US Food and Drug Administration (FDA) for its knee osteoarthritis drug.